Cite
Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A).
MLA
Hanna, M. G., et al. “Salbutamol Treatment in a Patient with Hyperkalaemic Periodic Paralysis Due to a Mutation in the Skeletal Muscle Sodium Channel Gene (SCN4A).” Journal of Neurology, Neurosurgery & Psychiatry, Aug. 1998, pp. 248–50. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=126271893&authtype=sso&custid=ns315887.
APA
Hanna, M. G., Stewart, J., Schapira, A. H., Wood, N. W., Morgan-Hughes, J. A., & Murray, N. M. (1998). Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). Journal of Neurology, Neurosurgery & Psychiatry, 248–250.
Chicago
Hanna, M G, J Stewart, A H Schapira, N W Wood, J A Morgan-Hughes, and N M Murray. 1998. “Salbutamol Treatment in a Patient with Hyperkalaemic Periodic Paralysis Due to a Mutation in the Skeletal Muscle Sodium Channel Gene (SCN4A).” Journal of Neurology, Neurosurgery & Psychiatry, August, 248–50. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=126271893&authtype=sso&custid=ns315887.